Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1
Autor: | Caroline Seynaeve, A. M. W. Van Den Ouweland, G. Dahmen, Mma Tilanus-Linthorst, C.T.M. Brekelmans, A.N. van Geel, E.J. Meijers-Heijboer, Anja Wagner, Lmc van den Bosch, J.G.M. Klijn, Peter Devilee, Ccm Bartels, L.C. Verhoog |
---|---|
Přispěvatelé: | Other departments, Medical Oncology, Surgery, Radiology & Nuclear Medicine, Clinical Genetics |
Rok vydání: | 1998 |
Předmět: |
Adult
Risk Oncology medicine.medical_specialty Pathology Mammary gland Genes BRCA1 Breast Neoplasms Biology Disease-Free Survival Germline mutation Breast cancer SDG 3 - Good Health and Well-being Internal medicine Immunopathology Odds Ratio Carcinoma Humans Medicine skin and connective tissue diseases Germ-Line Mutation Aged business.industry Mortality rate Hazard ratio Cancer Obstetrics and Gynecology General Medicine Middle Aged Prognosis medicine.disease Survival Analysis medicine.anatomical_structure Cancer research Female business |
Zdroj: | Lancet, 351(9099), 316-321. Elsevier Limited Lancet (UK), 351, 316-321. Elsevier Ltd. |
ISSN: | 0140-6736 |
Popis: | Hereditary breast cancer has been associated with mutations in the BRCA1 and BRCA2 genes and has a natural history different from sporadic breast cancer. We investigated disease-free and overall survival for patients with a proven BRCA1 alteration. We estimated disease-free and overall survival for 49 Dutch patients from 19 consecutive families with a proven specific BRCA1 mutation and one family with strong evidence for linkage to the BRCA1 gene. We compared clinical outcome and data on tumour size, histology, axillary nodal status, contralateral breast cancer, and oestrogen-receptor and progesterone-receptor status with those of 196 patients with sporadic breast cancer, matched for age and year of diagnosis. Disease-free survival for BRCA1 and sporadic patients at 5 years was 49% (95% CI 33-64) and 51% (43-59), respectively (p=0.98). Overall survival at 5 years was 63% (47-76) and 69% (62-76), respectively (p=0.88). Recurrence and death rates did not differ significantly between groups. Hazard ratios for recurrence and death among BRCA1 patients were 1.00 (0.65-1.55) and 1.04 (0.63-1.71) relative to sporadic patients (p=0.88), and these did not differ significantly after adjustment for prognostic factors. Patients with BRCA1-associated breast cancer had twice as many progesterone-receptor-negative tumours (p |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |